I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers.
Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR). I have also led trials of intratumoral immunotherapy and next-generation cytokine therapy.
In the laboratory, I run an extramurally funded translational program focused on the role of cytotoxic immune effectors in anti-tumor responses as well as immune-related adverse events (IRAEs) after immunotherapy. This work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems.
March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08AI139375
Harvard College, Cambridge, MA, AB, 06/2000, Biochemical Sciences
Stanford University School of Medicine, Stanford, CA, MD, 06/2011, Medicine
Stanford University School of Medicine, Stanford, CA, PhD, 06/2011, Molecular and Cellular Physiology
University of California, San Francisco, CA, Residency, 06/2014, Internal Medicine
University of California, San Francisco, CA, Fellowship, 06/2017, Hematology/Oncology